非小细胞肺癌的辅助化疗：效果渐失？ - Suppr

Suppr

超能文献

Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?

作者信息

Besse Benjamin, Le Chevalier Thierry

出版信息

J Clin Oncol. 2008 Nov 1;26(31):5014-7. doi: 10.1200/JCO.2008.18.1081. Epub 2008 Sep 22.

DOI:10.1200/JCO.2008.18.1081

PMID:18809602

Abstract

摘要

相似文献

Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?

J Clin Oncol. 2008 Nov 1;26(31):5014-7. doi: 10.1200/JCO.2008.18.1081. Epub 2008 Sep 22.

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1.

[Adjuvant chemotherapy in the early stages of non-small cell bronchial cancers].

Rev Pneumol Clin. 2002 Nov;58(5 Pt 2):3S31-2.

Chemotherapy helps patients with advanced non-small cell carcinoma of the lung.

N C Med J. 1996 Sep-Oct;57(5):281-6.

[Radio-chemotherapy combination in locally advanced, inoperable, non-small cell bronchial cancers].

Rev Pneumol Clin. 2002 Nov;58(5 Pt 2):3S37-41.

Mortality associated with pneumonectomy after induction chemoradiation versus chemotherapy alone in stage IIIA-N2 non-small cell lung cancer.

J Thorac Cardiovasc Surg. 2008 Mar;135(3):718; author reply 718-9. doi: 10.1016/j.jtcvs.2007.10.052.

Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.

Anticancer Res. 2007 Nov-Dec;27(6C):4481-9.

[Chemotherapy in cancer of the lung].

MMW Fortschr Med. 2006 Jun 1;148(22):33-4.

Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.

Lung Cancer. 2009 Aug;65(2):192-7. doi: 10.1016/j.lungcan.2009.03.027. Epub 2009 May 5.

[Clinical advances in the chemotherapy of non-small cell lung cancer].

Zhonghua Jie He He Hu Xi Za Zhi. 2004 Jul;27(7):480-2.

引用本文的文献

Alectinib impressively enters the adjuvant setting for early-stage -rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the most.

Transl Lung Cancer Res. 2025 Feb 28;14(2):310-313. doi: 10.21037/tlcr-24-961. Epub 2025 Feb 21.

Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis.

Mol Diagn Ther. 2019 Oct;23(5):657-665. doi: 10.1007/s40291-019-00419-9.

HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.

J Cancer Res Clin Oncol. 2014 Aug;140(8):1441-9. doi: 10.1007/s00432-014-1687-2. Epub 2014 Apr 27.

High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage I non-small cell lung cancer.

Oncol Lett. 2013 May;5(5):1461-1466. doi: 10.3892/ol.2013.1209. Epub 2013 Feb 22.

Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research.

J Exp Clin Cancer Res. 2011 Dec 29;30(1):115. doi: 10.1186/1756-9966-30-115.

Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.

Clin Cancer Res. 2011 Oct 1;17(19):6322-8. doi: 10.1158/1078-0432.CCR-11-1080. Epub 2011 Aug 10.

Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

J Clin Oncol. 2010 Jan 1;28(1):29-34. doi: 10.1200/JCO.2009.24.0333. Epub 2009 Nov 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验